Dr. Alexandra Marrs Bowling, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 245 North Street, Bristol, VA 24201 Phone: 276-669-4711 |
Shannon Finch, M D Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1318 Euclid Ave, Suite 2-3, Bristol, VA 24201 Phone: 276-466-0744 |
Dr. Andrea Annette Mcclintic, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 2195 Euclid Ave Ste 6, Bristol, VA 24201 Phone: 276-669-5179 Fax: 276-466-8870 |
Dr. Katie Cynthia Olubowale, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2195 Euclid Ave Ste 6, Bristol, VA 24201 Phone: 276-669-5179 |
Dr. Alex L Mcclintic, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3130 Lee Hwy Ste 201, Bristol, VA 24202 Phone: 276-645-4520 Fax: 276-645-0349 |
Roy Robert Andrews, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2195 Euclid Ave, Bristol, VA 24201 Phone: 276-669-5179 Fax: 276-466-8870 |
Darlene B Litton, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 410 Stagecoach Rd, Bristol, VA 24201 Phone: 276-466-0584 Fax: 276-669-8583 |
Jenna Lyn, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 917 Euclid Ave, Bristol, VA 24201 Phone: 305-610-2957 |
George Oliver Halstead, M.D. Family Medicine - Addiction Medicine Medicare: Accepting Medicare Assignments Practice Location: 2426 Lee Hwy, Bristol, VA 24202 Phone: 276-285-3911 Fax: 276-285-3920 |
Uzoma N Obuekwe, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2001 Euclid Ave, Bristol, VA 24201 Phone: 276-644-4433 Fax: 276-644-4434 |
News Archive
Post-traumatic stress disorder may increase the long-term risk for stroke and heart attack in blue-collar clean-up crews who worked in the aftermath of The World Trade Center plane attack on September 11, 2001, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program, earning a $25 million payment under the company's collaboration with Celgene Corporation.
The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.
People who are overweight in their twenties and become obese later in life may be three times more likely to develop cancer of either the oesophagus (food pipe) or upper stomach, according to a study published in the British Journal of Cancer today (Wednesday).
› Verified 1 days ago